Application of emodin in preparation of medicine for treating migraine

A technology for migraine, emodin, applied in the field of medicine

Pending Publication Date: 2021-12-21
CHINA PHARM UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, emodin can reduce the release of CGRP in the trigeminal ganglion and in

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of emodin in preparation of medicine for treating migraine
  • Application of emodin in preparation of medicine for treating migraine
  • Application of emodin in preparation of medicine for treating migraine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] 1. Materials and methods

[0028] 1. Test material

[0029] Emodin with a purity of 98% was purchased from Beijing Merida Technology Co., Ltd. (batch number M026282); ibuprofen granules were purchased from CSPC Group Co., Ltd. (batch number 363200601); sodium carboxymethylcellulose was purchased from Anhui Shanhe Pharmaceutical Excipients Co., Ltd. company (batch number 160511); urethane was purchased from Sinopharm Chemical Reagent Co., Ltd. (batch number 20190419); nitroglycerin injection was purchased from Beijing Yimin Pharmaceutical Co., Ltd. (batch number 20200310); emodin and ibuprofen granules were respectively used with 0.5% Sodium carboxymethylcellulose was dissolved for administration. 48 SD rats (180-220g), half male and half male, were purchased from Nanjing Qinglongshan Animal Factory (certificate number: 20210105Aazz0100000962, production license number: SCXK (Zhejiang) 2019-0002). Referring to the method in the literature, the animals were reared in an...

Embodiment 2

[0062] Embodiment 2 The preparation example of medicine for the treatment of migraine

[0063] 1. Materials and methods

[0064] 1. Test material

[0065]Isopropyl myristate (IPM, Linyi Green Forest), isopropyl palmitate (IPP, Linyi Green Forest), castor oil polyoxyethylene (EL-40, Aladdin), sodium polyacrylate 700 (NP700, American International Tepin Company), Carbomer (CP-934, Langfang Jutong Chemical Co., Ltd.), Polyoxyethylene Hydrogenated Castor Oil (RH-40, BASF Company), Poloxamer 407 (P407), Poloxamer 188 (P188) were all purchased from Shandong Youso Chemical Technology Co., Ltd., and the purity of emodin was 98%. Latin Reagent Co., Ltd.), hydroxypropyl methylcellulose (Shanghai Yuanye Biotechnology Co., Ltd.), lactose (Zhenjiang Kangfu Bioengineering Co., Ltd.), absolute ethanol (analytical grade, Shanghai Titan Chemical Co., Ltd.).

[0066] 2. Preparation of Emodin Nanoemulsion Gel Nasal Drops

[0067] First, the oil phase Lauroglycol FCC, Labrafac PG, isopropyl m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Hardnessaaaaaaaaaa
Login to view more

Abstract

The invention discloses application of emodin in preparation of a medicine for treating migraine. The research finds that 1, the emodin can inhibit the generation of NO, relieve the excessive expansion of blood vessels and prevent and treat the migraine from the source; 2, the emodin reduces release of inflammatory factors TNF-alpha, so that inflammatory response is inhibited; 3, the emodin can reduce the release of vascular neuropeptide CGRP and P substances; and 4, the emodin can inhibit the expression of PKG protein of migraine rats and relieve vasodilation. Therefore, the possibility of the emodin serving as an anti-migraine medicine is shown in various modes, and the emodin is expected to become a novel small molecule medicine for clinically treating migraine.

Description

Technical field: [0001] The invention belongs to the field of medicine, and in particular relates to the application of emodin in the preparation of medicines for treating migraine. Background technique: [0002] Migraine is a primary central nervous system dysfunction disease characterized by unilateral or bilateral throbbing headaches. After being stimulated, neuropeptides such as substance P (SP), neurokinin A (NKA), and calcitonin gene-related peptide (CGRP) are released, causing excessive expansion of the vessel walls of adjacent intracranial vessels, resulting in fluctuating headaches. [0003] The current drugs for treating migraine include: calcium ion antagonists, 5-HT1B / 1D receptor agonists, α-adrenergic receptor blockers, CGRP receptor antagonists, non-steroidal anti-inflammatory drugs, etc., but they all exist Certain toxic side effects. At present, different types of migraine treatment drugs cannot meet the treatment needs due to insufficient curative effect, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/122A61P25/06
CPCA61K31/122A61P25/06
Inventor 张春凤孙淑汀
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap